Pilot scale production of the vaccine adjuvant Proteoliposome derived Cochleates (AFCo1) from Neisseria meningitidis serogroup B

The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant Finlay Cochleate 1, derived from proteoliposomes of N. meningitidis B) using a dialysis pr...

Full description

Saved in:
Bibliographic Details
Published inBMC immunology Vol. 14; no. Suppl 1; p. S4
Main Authors Zayas, Caridad, González, Domingo, Acevedo, Reinaldo, del Campo, Judith, Lastre, Miriam, González, Elizabeth, Romeu, Belkis, Cuello, Maribel, Balboa, Julio, Cabrera, Osmir, Guilherme, Luisa, Pérez, Oliver
Format Journal Article
LanguageEnglish
Published London BioMed Central 2013
Subjects
Online AccessGet full text
ISSN1471-2172
1471-2172
DOI10.1186/1471-2172-14-S1-S4

Cover

Abstract The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant Finlay Cochleate 1, derived from proteoliposomes of N. meningitidis B) using a dialysis procedure to produce them on lab scale. The immunogenicity of the AFCo1 produced by dialysis has been already evaluated, but it was necessary to demonstrate the feasibility of a larger-scale manufacturing process. Therefore, we used a crossflow diafiltration system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The aim of this work was to produce AFCo1 on pilot scale, while conserving the adjuvant properties. The proteoliposomes (raw material) were resuspended in a buffer containing sodium deoxycholate and were transformed into AFCo1 under the action of a calcium forming buffer. The detergent was removed from the protein solution by diafiltration to a constant volume. In this CFS, we used a hollow fiber cartridge from Amicon (polysulfona cartridge of 10 kDa porosity, 1mm channel diameter of fiber and 0.45 m 2 area of filtration), allowing production of a batch of up to 20 L. AFCo1 were successfully produced by tangential filtration to pilot scale. The batch passed preliminary stability tests. Nasal immunization of BALB/c mice, induced specific saliva IgA and serum IgG. The induction of Th1 responses were demonstrated by the induction of IgG2a, IFNγ and not IL-5. The adjuvant action over Neisseria (self) antigens and with co-administered (heterologous) antigens such as ovalbumin and a synthetic peptide from haemolytic Streptococcus B was also demonstrated.
AbstractList Doc number: S4 Abstract: The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant Finlay Cochleate 1, derived from proteoliposomes of N. meningitidis B) using a dialysis procedure to produce them on lab scale. The immunogenicity of the AFCo1 produced by dialysis has been already evaluated, but it was necessary to demonstrate the feasibility of a larger-scale manufacturing process. Therefore, we used a crossflow diafiltration system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The aim of this work was to produce AFCo1 on pilot scale, while conserving the adjuvant properties. The proteoliposomes (raw material) were resuspended in a buffer containing sodium deoxycholate and were transformed into AFCo1 under the action of a calcium forming buffer. The detergent was removed from the protein solution by diafiltration to a constant volume. In this CFS, we used a hollow fiber cartridge from Amicon (polysulfona cartridge of 10 kDa porosity, 1mm channel diameter of fiber and 0.45 m2 area of filtration), allowing production of a batch of up to 20 L. AFCo1 were successfully produced by tangential filtration to pilot scale. The batch passed preliminary stability tests. Nasal immunization of BALB/c mice, induced specific saliva IgA and serum IgG. The induction of Th1 responses were demonstrated by the induction of IgG2a, IFNγ and not IL-5. The adjuvant action over Neisseria (self) antigens and with co-administered (heterologous) antigens such as ovalbumin and a synthetic peptide from haemolytic Streptococcus B was also demonstrated.
The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant Finlay Cochleate 1, derived from proteoliposomes of N. meningitidis B) using a dialysis procedure to produce them on lab scale. The immunogenicity of the AFCo1 produced by dialysis has been already evaluated, but it was necessary to demonstrate the feasibility of a larger-scale manufacturing process. Therefore, we used a crossflow diafiltration system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The aim of this work was to produce AFCo1 on pilot scale, while conserving the adjuvant properties. The proteoliposomes (raw material) were resuspended in a buffer containing sodium deoxycholate and were transformed into AFCo1 under the action of a calcium forming buffer. The detergent was removed from the protein solution by diafiltration to a constant volume. In this CFS, we used a hollow fiber cartridge from Amicon (polysulfona cartridge of 10 kDa porosity, 1mm channel diameter of fiber and 0.45 m² area of filtration), allowing production of a batch of up to 20 L. AFCo1 were successfully produced by tangential filtration to pilot scale. The batch passed preliminary stability tests. Nasal immunization of BALB/c mice, induced specific saliva IgA and serum IgG. The induction of Th1 responses were demonstrated by the induction of IgG2a, IFNγ and not IL-5. The adjuvant action over Neisseria (self) antigens and with co-administered (heterologous) antigens such as ovalbumin and a synthetic peptide from haemolytic Streptococcus B was also demonstrated.The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant Finlay Cochleate 1, derived from proteoliposomes of N. meningitidis B) using a dialysis procedure to produce them on lab scale. The immunogenicity of the AFCo1 produced by dialysis has been already evaluated, but it was necessary to demonstrate the feasibility of a larger-scale manufacturing process. Therefore, we used a crossflow diafiltration system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The aim of this work was to produce AFCo1 on pilot scale, while conserving the adjuvant properties. The proteoliposomes (raw material) were resuspended in a buffer containing sodium deoxycholate and were transformed into AFCo1 under the action of a calcium forming buffer. The detergent was removed from the protein solution by diafiltration to a constant volume. In this CFS, we used a hollow fiber cartridge from Amicon (polysulfona cartridge of 10 kDa porosity, 1mm channel diameter of fiber and 0.45 m² area of filtration), allowing production of a batch of up to 20 L. AFCo1 were successfully produced by tangential filtration to pilot scale. The batch passed preliminary stability tests. Nasal immunization of BALB/c mice, induced specific saliva IgA and serum IgG. The induction of Th1 responses were demonstrated by the induction of IgG2a, IFNγ and not IL-5. The adjuvant action over Neisseria (self) antigens and with co-administered (heterologous) antigens such as ovalbumin and a synthetic peptide from haemolytic Streptococcus B was also demonstrated.
The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant Finlay Cochleate 1, derived from proteoliposomes of N. meningitidis B) using a dialysis procedure to produce them on lab scale. The immunogenicity of the AFCo1 produced by dialysis has been already evaluated, but it was necessary to demonstrate the feasibility of a larger-scale manufacturing process. Therefore, we used a crossflow diafiltration system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The aim of this work was to produce AFCo1 on pilot scale, while conserving the adjuvant properties. The proteoliposomes (raw material) were resuspended in a buffer containing sodium deoxycholate and were transformed into AFCo1 under the action of a calcium forming buffer. The detergent was removed from the protein solution by diafiltration to a constant volume. In this CFS, we used a hollow fiber cartridge from Amicon (polysulfona cartridge of 10 kDa porosity, 1mm channel diameter of fiber and 0.45 m 2 area of filtration), allowing production of a batch of up to 20 L. AFCo1 were successfully produced by tangential filtration to pilot scale. The batch passed preliminary stability tests. Nasal immunization of BALB/c mice, induced specific saliva IgA and serum IgG. The induction of Th1 responses were demonstrated by the induction of IgG2a, IFNγ and not IL-5. The adjuvant action over Neisseria (self) antigens and with co-administered (heterologous) antigens such as ovalbumin and a synthetic peptide from haemolytic Streptococcus B was also demonstrated.
The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant Finlay Cochleate 1, derived from proteoliposomes of N. meningitidis B) using a dialysis procedure to produce them on lab scale. The immunogenicity of the AFCo1 produced by dialysis has been already evaluated, but it was necessary to demonstrate the feasibility of a larger-scale manufacturing process. Therefore, we used a crossflow diafiltration system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The aim of this work was to produce AFCo1 on pilot scale, while conserving the adjuvant properties. The proteoliposomes (raw material) were resuspended in a buffer containing sodium deoxycholate and were transformed into AFCo1 under the action of a calcium forming buffer. The detergent was removed from the protein solution by diafiltration to a constant volume. In this CFS, we used a hollow fiber cartridge from Amicon (polysulfona cartridge of 10 kDa porosity, 1mm channel diameter of fiber and 0.45 m super(2) area of filtration), allowing production of a batch of up to 20 L. AFCo1 were successfully produced by tangential filtration to pilot scale. The batch passed preliminary stability tests. Nasal immunization of BALB/c mice, induced specific saliva IgA and serum IgG. The induction of Th1 responses were demonstrated by the induction of IgG2a, IFN[gamma] and not IL-5. The adjuvant action over Neisseria (self) antigens and with co-administered (heterologous) antigens such as ovalbumin and a synthetic peptide from haemolytic Streptococcus B was also demonstrated.
The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant Finlay Cochleate 1, derived from proteoliposomes of N. meningitidis B) using a dialysis procedure to produce them on lab scale. The immunogenicity of the AFCo1 produced by dialysis has been already evaluated, but it was necessary to demonstrate the feasibility of a larger-scale manufacturing process. Therefore, we used a crossflow diafiltration system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The aim of this work was to produce AFCo1 on pilot scale, while conserving the adjuvant properties. The proteoliposomes (raw material) were resuspended in a buffer containing sodium deoxycholate and were transformed into AFCo1 under the action of a calcium forming buffer. The detergent was removed from the protein solution by diafiltration to a constant volume. In this CFS, we used a hollow fiber cartridge from Amicon (polysulfona cartridge of 10 kDa porosity, 1mm channel diameter of fiber and 0.45 m² area of filtration), allowing production of a batch of up to 20 L. AFCo1 were successfully produced by tangential filtration to pilot scale. The batch passed preliminary stability tests. Nasal immunization of BALB/c mice, induced specific saliva IgA and serum IgG. The induction of Th1 responses were demonstrated by the induction of IgG2a, IFNγ and not IL-5. The adjuvant action over Neisseria (self) antigens and with co-administered (heterologous) antigens such as ovalbumin and a synthetic peptide from haemolytic Streptococcus B was also demonstrated.
ArticleNumber S4
Author González, Domingo
Lastre, Miriam
Cabrera, Osmir
Pérez, Oliver
Zayas, Caridad
Cuello, Maribel
Balboa, Julio
del Campo, Judith
Romeu, Belkis
Acevedo, Reinaldo
González, Elizabeth
Guilherme, Luisa
AuthorAffiliation 1 Finlay Institute. Ave. 27 No. 19805, La Lisa. Havana, Cuba. AP. 16017, CP11600
2 Heart Institute (InCor) of Sao Paulo, Brazil
AuthorAffiliation_xml – name: 1 Finlay Institute. Ave. 27 No. 19805, La Lisa. Havana, Cuba. AP. 16017, CP11600
– name: 2 Heart Institute (InCor) of Sao Paulo, Brazil
Author_xml – sequence: 1
  givenname: Caridad
  surname: Zayas
  fullname: Zayas, Caridad
  email: czayas@finlay.edu.cu
  organization: Finlay Institute
– sequence: 2
  givenname: Domingo
  surname: González
  fullname: González, Domingo
  organization: Finlay Institute
– sequence: 3
  givenname: Reinaldo
  surname: Acevedo
  fullname: Acevedo, Reinaldo
  organization: Finlay Institute
– sequence: 4
  givenname: Judith
  surname: del Campo
  fullname: del Campo, Judith
  organization: Finlay Institute
– sequence: 5
  givenname: Miriam
  surname: Lastre
  fullname: Lastre, Miriam
  organization: Finlay Institute
– sequence: 6
  givenname: Elizabeth
  surname: González
  fullname: González, Elizabeth
  organization: Finlay Institute
– sequence: 7
  givenname: Belkis
  surname: Romeu
  fullname: Romeu, Belkis
  organization: Finlay Institute
– sequence: 8
  givenname: Maribel
  surname: Cuello
  fullname: Cuello, Maribel
  organization: Finlay Institute
– sequence: 9
  givenname: Julio
  surname: Balboa
  fullname: Balboa, Julio
  organization: Finlay Institute
– sequence: 10
  givenname: Osmir
  surname: Cabrera
  fullname: Cabrera, Osmir
  organization: Finlay Institute
– sequence: 11
  givenname: Luisa
  surname: Guilherme
  fullname: Guilherme, Luisa
  organization: Heart Institute (InCor) of Sao Paulo
– sequence: 12
  givenname: Oliver
  surname: Pérez
  fullname: Pérez, Oliver
  organization: Finlay Institute
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23458578$$D View this record in MEDLINE/PubMed
BookMark eNqNkk9v1DAQxSNURP_AF-CALHEph4DHcWLngtSuKEWqoNLC2XKcya5Xib3Yzkrc-Ogk2rbaVgJx8mj8e0_PnjnNjpx3mGWvgb4HkNUH4AJyBoLlwPMl5Ev-LDt5aB4d1MfZaYwbSkFIJl9kx6zgpSyFPMl-39reJxKN7pFsg29Hk6x3xHckrZHstDHWIdHtZtxpl8ht8Al9b7c--gFJi8HusCULb9Y96oSRnF9cLTy8I13wA_mKNsaJ0WRAZ93KJtvaSKaWXwU_bsnly-x5p_uIr-7Os-zH1afvi-v85tvnL4uLm9yUVKQcdNs1phKi5NI0iAzqUhSMQcd00dAOsaNQsBo1VqypdNliDU1FG951tCrL4iz7uPfdjs2ArUGXgu7VNthBh1_Ka6se3zi7Viu_U0UpGefVZHB-ZxD8zxFjUoONBvteO_RjVFBUgssaKvofKAhOK1bPsd4-QTd-DG76iZmaZieBz9Sbw_APqe_nOAFyD5jgYwzYKWOTnic5vcX2CqiaV0bNG6HmjZgqtQS15JOUPZHeu_9TVOxFcYLdCsNB7L-r_gD2RtWm
CitedBy_id crossref_primary_10_1016_j_ijpharm_2014_04_002
crossref_primary_10_1016_j_msec_2019_110410
crossref_primary_10_1007_s11427_014_4769_0
crossref_primary_10_1016_j_ejpb_2017_04_030
crossref_primary_10_1016_j_intimp_2021_107411
Cites_doi 10.1038/nm0602-567
10.1586/14760584.6.5.723
10.1111/j.1365-3083.2007.01981.x
10.1016/j.ymeth.2009.03.025
ContentType Journal Article
Copyright Zayas et al; licensee BioMed Central Ltd. 2013
2013 Zayas et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright ©2013 Zayas et al; licensee BioMed Central Ltd. 2013 Zayas et al; licensee BioMed Central Ltd.
Copyright_xml – notice: Zayas et al; licensee BioMed Central Ltd. 2013
– notice: 2013 Zayas et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
– notice: Copyright ©2013 Zayas et al; licensee BioMed Central Ltd. 2013 Zayas et al; licensee BioMed Central Ltd.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7T5
7X7
7XB
88E
8C1
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
7QL
C1K
5PM
DOI 10.1186/1471-2172-14-S1-S4
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest : Biological Science Collection journals [unlimited simultaneous users]
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
Bacteriology Abstracts (Microbiology B)
Environmental Sciences and Pollution Management
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
Bacteriology Abstracts (Microbiology B)
Environmental Sciences and Pollution Management
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic

AIDS and Cancer Research Abstracts
MEDLINE

Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1471-2172
EndPage S4
ExternalDocumentID PMC3582446
2900543531
23458578
10_1186_1471_2172_14_S1_S4
Genre Journal Article
GeographicLocations Cuba
GeographicLocations_xml – name: Cuba
GroupedDBID ---
0R~
23N
2WC
4.4
53G
5VS
6J9
7X7
88E
8C1
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HCIFZ
HMCUK
HYE
IAO
IHR
INH
INR
ISR
ITC
KQ8
LK8
M1P
M48
M7P
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
AAYXX
ALIPV
CITATION
123
2VQ
C1A
CGR
CUY
CVF
ECM
EIF
IPNFZ
LGEZI
LOTEE
NADUK
NPM
NXXTH
RIG
3V.
7T5
7XB
8FK
AZQEC
DWQXO
GNUQQ
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
7QL
C1K
5PM
ID FETCH-LOGICAL-c507t-1adfbc677548cbee219573221f2a3b0feef01329eae62b6a5de91b60b4ff06553
IEDL.DBID M48
ISSN 1471-2172
IngestDate Thu Aug 21 18:14:08 EDT 2025
Fri Sep 05 13:04:33 EDT 2025
Fri Sep 05 13:34:42 EDT 2025
Fri Jul 25 19:26:01 EDT 2025
Thu Apr 03 06:55:03 EDT 2025
Tue Jul 01 03:29:38 EDT 2025
Thu Apr 24 23:01:50 EDT 2025
Sat Sep 06 07:25:15 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Suppl 1
Keywords Heterologous Antigen
Pilot Scale
Adjuvant Property
Haemolytic Streptococcus
Calcium Buffer
Language English
License http://creativecommons.org/licenses/by/2.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c507t-1adfbc677548cbee219573221f2a3b0feef01329eae62b6a5de91b60b4ff06553
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Conference-3
SourceType-Conference Papers & Proceedings-2
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/1471-2172-14-S1-S4
PMID 23458578
PQID 1312178145
PQPubID 44823
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3582446
proquest_miscellaneous_1367489160
proquest_miscellaneous_1317406295
proquest_journals_1312178145
pubmed_primary_23458578
crossref_citationtrail_10_1186_1471_2172_14_S1_S4
crossref_primary_10_1186_1471_2172_14_S1_S4
springer_journals_10_1186_1471_2172_14_S1_S4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-00-00
PublicationDateYYYYMMDD 2013-01-01
PublicationDate_xml – year: 2013
  text: 2013-00-00
PublicationDecade 2010
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle BMC immunology
PublicationTitleAbbrev BMC Immunol
PublicationTitleAlternate BMC Immunol
PublicationYear 2013
Publisher BioMed Central
Publisher_xml – name: BioMed Central
References J del Campo (501_CR8) 2009; 49
C Campa (501_CR3) 1997
P Kidd (501_CR9) 2003; 8
D Mora (501_CR11) 2006; 24
501_CR1
T Meltzer (501_CR5) 1998
JF Infante (501_CR10) 2010; 18
X Ferriol (501_CR6) 1999; 51
C Zayas (501_CR4) 2006; 24
MF Neurath (501_CR7) 2002; 8
O Pérez (501_CR2) 2007; 66
16823944 - Vaccine. 2006 Apr 12;24 Suppl 2:S2-94-5
10887568 - Rev Cubana Med Trop. 1999 May-Aug;51(2):99-105
17931153 - Expert Rev Vaccines. 2007 Oct;6(5):723-39
17635804 - Scand J Immunol. 2007 Aug-Sep;66(2-3):271-7
12042806 - Nat Med. 2002 Jun;8(6):567-73
12946237 - Altern Med Rev. 2003 Aug;8(3):223-46
19410000 - Methods. 2009 Dec;49(4):301-8
16823941 - Vaccine. 2006 Apr 12;24 Suppl 2:S2-88-9
References_xml – volume: 8
  start-page: 223
  issue: 3
  year: 2003
  ident: 501_CR9
  publication-title: Altern Med Rev
– volume: 24
  start-page: S2
  issue: S2
  year: 2006
  ident: 501_CR4
  publication-title: Vaccine
– volume-title: Marcel Dekker Inc
  year: 1998
  ident: 501_CR5
– volume: 8
  start-page: 567
  issue: 6
  year: 2002
  ident: 501_CR7
  publication-title: Nature Medicine
  doi: 10.1038/nm0602-567
– volume: 24
  start-page: S2
  issue: S2
  year: 2006
  ident: 501_CR11
  publication-title: Vaccine
– ident: 501_CR1
  doi: 10.1586/14760584.6.5.723
– volume: 51
  start-page: 99
  issue: 2
  year: 1999
  ident: 501_CR6
  publication-title: Revista Cubana de Medicina Tropical
– volume: 66
  start-page: 271
  year: 2007
  ident: 501_CR2
  publication-title: Scandinavian Journal of Immunology
  doi: 10.1111/j.1365-3083.2007.01981.x
– volume: 18
  start-page: 1
  issue: 1
  year: 2010
  ident: 501_CR10
  publication-title: Vaccimonitor
– volume: 49
  start-page: 301
  issue: 4
  year: 2009
  ident: 501_CR8
  publication-title: Methods
  doi: 10.1016/j.ymeth.2009.03.025
– volume-title: USPTO
  year: 1997
  ident: 501_CR3
– reference: 17931153 - Expert Rev Vaccines. 2007 Oct;6(5):723-39
– reference: 17635804 - Scand J Immunol. 2007 Aug-Sep;66(2-3):271-7
– reference: 12946237 - Altern Med Rev. 2003 Aug;8(3):223-46
– reference: 16823941 - Vaccine. 2006 Apr 12;24 Suppl 2:S2-88-9
– reference: 12042806 - Nat Med. 2002 Jun;8(6):567-73
– reference: 10887568 - Rev Cubana Med Trop. 1999 May-Aug;51(2):99-105
– reference: 16823944 - Vaccine. 2006 Apr 12;24 Suppl 2:S2-94-5
– reference: 19410000 - Methods. 2009 Dec;49(4):301-8
SSID ssj0017828
Score 1.991475
Snippet The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a...
Doc number: S4 Abstract: The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed....
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage S4
SubjectTerms Adjuvants, Immunologic - administration & dosage
Administration, Intranasal
Allergology
Animals
Antibodies, Bacterial - blood
Antibodies, Bacterial - immunology
Biomedical and Life Sciences
Biomedicine
Cytokines and Growth Factors
Drug dosages
Experiments
Immunization
Immunoglobulin A - blood
Immunoglobulin A - immunology
Immunoglobulin G - blood
Immunoglobulin G - immunology
Immunology
Interferon-gamma - biosynthesis
Interleukin-5 - biosynthesis
Licensed products
Medical research
Meningococcal Vaccines - biosynthesis
Mice
Mice, Inbred BALB C
Neisseria
Neisseria meningitidis
Neisseria meningitidis, Serogroup B - immunology
Ovalbumin - immunology
Pilot Projects
Proceedings
Proteolipids - immunology
Raw materials
Streptococcus
Studies
Th1 Cells - immunology
Toxicity
Vaccine
Vaccines
SummonAdditionalLinks – databaseName: Health & Medical Collection (ProQuest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96ovgien5VT4ngg6Lhmjb92Cc5F5dDuONgPdi3kjQTrsdes9rugW_-6c70Y3U93LfSTCHpTJLfZDLzY-xtFhsHodQCohCEKg0Io0AJa8l9dhnu2ZScfHKaHp-rr4tkMRy4NcO1ynFN7BZq60s6Iz-UsUT0nEuVfFp9F8QaRdHVgULjNrsjEaqQVWeLjcOF4lE-Jsrk6aHEhVgQIZOQSsylmKvtzegGwrx5UfKfaGm3Cc0esgcDeuRHvbofsVtQ77O7PZ_kz31272SIlD9mv86qpW95gyoAvurLuqIKuHccIR-_1iXJcW0v14ilW35G9Rr8slr5xl8Bt2iY12D51JcXSyA8yt8dzaZevueUkMJPoYvjV5pfQc95VNmq4fjKd3ki_PMTdj778m16LAa2BVEiJmyF1NaZMqWKeDmqDHApSzKc7tJFOjahA3AUl5mAhjQyqU4sTKRJQ6OcQxyTxE_ZXu1reM44hWqNjdLI2UjFNs6dLLXMUNqUVod5wOT424tyKEVOjBjLonNJ8rQgVRWkKnwq5rKYq4B92Hyz6gtx7JQ-GLVZDJOyKf6YUMDebJpxOlGMRNfg151MhhgnmuyUIYYWxNVhwJ71BrLpUhQrdMAyHGK2ZTobASrnvd1SVxddWW_KWUbnPGAfRyP7q-v_HemL3SN9ye5HHYEHHRodsL32xxpeIYxqzeturvwGj3QdCA
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9RAEF-0ovgitWobbWUFHxRdzCabj3tsg0cRWgpnoW9hNztLI9fs4eUKvvmnO5PkQs_Wgm8hmYXdnZmd32R2Zhh7n8XGQSi1gCgEoSoDwihQwlpyn12GNpuSk09O0-Nz9e0iuRjK5FAuzM34vczTLxIPT0FNlIRUYibFTD1kjxI8eOn6XpEWY8QALV2-Toq5c9ym4bmFJm9fivwrMtoZnOk2ezYgRX7Ys_Y5ewDNDnvc9478tcOenAxR8Rfs91k99y1f4nYDX_QlXHG7uXcc4R2_1hXRcW1_rBA3t_yMajP4eb3wS38F3KIQXoPlha8u50DYk384nBZefuSUfMJPoYvZ15pfQd_fqLb1kuMr3-WE8KOX7Hz69XtxLIbOCqJC_NcKqa0zVUrV73JkD-CxlWSo2tJFOjahA3AUg5mAhjQyqU4sTKRJQ6OcQ8ySxK_YVuMb2GOcwrLGRmnkbKRiG-dOVlpmSG0qq8M8YHK97WU1lB2n7hfzsnM_8rQkVpXEKnwqZ7KcqYB9Gscs-qIb91Lvr7lZDgq4LGUskSiXKgnYu_Ezqg7FQ3QDftXRZIhnosm9NNSNBTF0GLDdXkDGKUWxQmcrwyVmG6IzElDp7s0vTX3ZlfCm_GR0xAP2eS1kN6b-z5W-_j_yN-xp1DXvoB9G-2yr_bmCA4RQrXnb6c4fko0WDA
  priority: 102
  providerName: Springer Nature
Title Pilot scale production of the vaccine adjuvant Proteoliposome derived Cochleates (AFCo1) from Neisseria meningitidis serogroup B
URI https://link.springer.com/article/10.1186/1471-2172-14-S1-S4
https://www.ncbi.nlm.nih.gov/pubmed/23458578
https://www.proquest.com/docview/1312178145
https://www.proquest.com/docview/1317406295
https://www.proquest.com/docview/1367489160
https://pubmed.ncbi.nlm.nih.gov/PMC3582446
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central Open Access Free
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: RBZ
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: KQ8
  dateStart: 20001101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: KQ8
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: DOA
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: Academic Search Ultimate - eBooks
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: ABDBF
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: DIK
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: M~E
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: RPM
  dateStart: 20000101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Health & Medical Collection
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: 8C1
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: M48
  dateStart: 20001101
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: Springer Nature HAS Fully OA
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: AAJSJ
  dateStart: 20001201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 1471-2172
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017828
  issn: 1471-2172
  databaseCode: C6C
  dateStart: 20001201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_tQyBeEIyvwKiMxAMIDHHiJukDQlu0akJqVVEq9S2yY1sLypqythN740_nLmnKxsYeeImS-KIkvrPv51zufgCv41A76wvFbeBbLnNtuZZWcmNo-exi9NmUnDwYRscT-WXanW5BS3e07sDFjUs74pOanJUffv64-IwD_lM94JPoo8AJlhPREheSjwUfy23YRc8UkJUP5J-oAnrDpE2cufE6Kg0cSkTQxLp22U9dA5_X_6H8K5Ba-6f-A7i_BpbsoLGEh7BlZ3twp6GavNiDu4N1EP0R_BoVZbVkC9SOZfOm4itqh1WOIRpk5yonOabM9xXC7CUbUSmHqizm1aI6tcygzZ5bw9IqPyktQVX25qCfVuIto1wVNrR1iL9Q7NQ2dEiFKRYMT1V1Cgk7fAyT_tG39JiviRh4jnBxyYUyTucRFctLUJsWZ7lujDOBcIEKte-sdRSy6Vllo0BHqmtsT-jI19I5hDjd8AnszKqZfQaMorjaBFHgTCBDEyZO5ErEKK1zo_zEA9F2e5avq5QTWUaZ1auVJMpIaxlpDfeyscjG0oN3m2vmTY2OW6X3W21mrbllIhQolAjZ9eDVphlHGoVP1MxWq1omRvgT9G6VIfIWhNy-B08bA9k8UmtZHsRXTGcjQJW-r7bMipO64jelM-O63YP3rZFdevR_vunz_77RC7gX1LQf9KlpH3aWZyv7EsHXUndgO57GuE1S0YHdw6Ph6CsepVHaqT9ndOoR9xsJHTK4
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemIT5eEIyvwgAjgQRi1mLHTdIHhEah6thaTeom9S3Y8UUL6upC26G98RfxN3KXNIUy0be9Vc1Vsnsf_l3Odz_GXsahzSGQRoAKQOjMgrAatHCO0uc8xjObmpN7_ah7oj8Pm8MN9qvuhaFrlXVMLAO18xm9I9-VoUT0nEjdfD_5Jog1iqqrNYVGZRYHcPEDU7bpu_2PqN9XSnU-Hbe7YsEqIDLEPjMhjcttFtHktwSXBuiyzRjNWubKhDbIAXKqP7TAQKRsZJoOWtJGgdV5juc1sURgyL-mw0DTrP54uEzwcHkqqRtzkmhXYuAXRAAlpBYDKQZ69fC7hGgvX8z8pzpbHnqdO-z2Aq3yvcq87rINGG-x6xV_5cUWu9FbVObvsZ9HxcjP-BRVDnxSjZFFlXOfc4SY_NxkJMeN-zpH7D7jRzQfwo-KiZ_6M-AOHeEcHG_77HQEhH_5671O28s3nBpgeB_KewOF4WdQcSwVrphy_MqXfSn8w312ciV6eMA2x34Mjxin0rB1KlK5Uzp0YZLLzMgYpW3mTJA0mKz_9jRbjD4nBo5RWqZASZSSqlJSFX5KBzId6AZ7u_zNpBr8sVZ6u9ZmuggC0_SPyTbYi-VjdF-qyZgx-HkpEyOmUq21MsQIgzg-aLCHlYEsl6RCjQlfjFuMV0xnKUDjw1efjIvTcow49UhrHTXYTm1kfy39vzt9vH6nz9nN7nHvMD3c7x88YbdUSR5CL6y22ebs-xyeIoSb2Wel33D25aod9TdPoVqs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgExMvCAaMwAAj8QACa3HifPSxFKpRWFUpTNpbZMdnLaiLK5pO4o0_nXO-tDKYxFsUnyU7d-f7Xc53R8jrJFQGfC4ZBD4wUShgSoBgWjv32SRos11y8sk8Pj4Vs7Po7EoWf3PbvQ9JtjkNrkpTVR-ttGlVPI2POB6pzLVWYlywjLNM3Ca7aTSK0f3aHY9n2WyIJKAFTPtkmb_O3DZI11Dm9cuSf0RMG0M0vU_udQiSjluWPyC3oNond9qekj_3yd5JFy1_SH4tyqWt6RrZAHTVlnZFNlBrKMI-eikLR0el_r5BPF3ThavZYJflyq7tBVCNwnkJmk5scb4Eh0npm_F0Yvlb6pJS6ByaWH4p6QW0fY9KXa4pvrJNrgj98IicTj99mxyzruMCKxAX1oxLbVQRu6p4KbIN8DiLElR5bgIZKt8AGBebGYGEOFCxjDSMuIp9JYxBLBOFj8lOZSt4QqgL1yodxIHRgQh1mBpeSJ4gtSq09FOP8P6z50VXjtx1xVjmjVuSxrljVe5YhU95xvNMeOTdMGfVFuO4kfqw52beKeY65yFHopSLyCOvhmFUKRcnkRXYTUOTIM4JRjfSuC4tiK19jxy0AjIsKQgFOmEJbjHZEp2BwJX03h6pyvOmtLfLW0YH3SPveyG7svR_7vTp_5G_JHuLj9P86-f5l2fkbtD093D_lA7JTv1jA88RZdXqRadIvwF6WCK3
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pilot+scale+production+of+the+vaccine+adjuvant+Proteoliposome+derived+Cochleates+%28AFCo1%29+from+Neisseria+meningitidis+serogroup+B&rft.jtitle=BMC+immunology&rft.au=Zayas%2C+Caridad&rft.au=Gonz%C3%A1lez%2C+Domingo&rft.au=Acevedo%2C+Reinaldo&rft.au=del+Campo%2C+Judith&rft.date=2013&rft.pub=BioMed+Central&rft.eissn=1471-2172&rft.volume=14&rft.issue=Suppl+1&rft.spage=S4&rft.epage=S4&rft_id=info:doi/10.1186%2F1471-2172-14-S1-S4&rft_id=info%3Apmid%2F23458578&rft.externalDocID=PMC3582446
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2172&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2172&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2172&client=summon